Korean J Endocr Surg.  2010 Mar;10(1):24-28. 10.16956/kjes.2010.10.1.24.

Analysis of the Clinicopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma

• Lee MW
• Ha TK
• Ryu SM
• Kim SH

• KMID: 2375729
• DOI: http://doi.org/10.16956/kjes.2010.10.1.24

Abstract

PURPOSE
Papillary thyroid carcinoma (PTC) is the most common malignancy that develops from the thyroid gland and its prognosis is quite excellent. One of the characteristic behaviors of PTC is that it often occurs at multiple foci. The purpose of this study was to investigate the clinicopathologic features and risk factors of multifocal papillary thyroid cancer.
METHODS
A retrospective review was carried out on 624 patients with PTC and who underwent surgery from January 2005 to December 2007. Two hundred twenty-nine of them were found to have multiple tumor foci (≥2 foci). The risk factors that included gender, age at diagnosis, tumor size, capsular invasion, extrathyroidal extension (ETE), cervical lymph node (LN) involvement, the TNM classification, local recurrence and distant metastasis were comparatively analyzed between the solitary PTC and multifocal PTC groups.
RESULTS
The enrolled patients were 59 male and 565 females. The mean age was 46 years (range: 15~77 years). Age (P=0.025), tumor size (P=0.027), capsular invasion (P<0.001), ETE (P<0.001) and cervical LN metastasis (P=0.002) were the significantly related factors for multifocal papillary thyroid cancer. However, gender was not significantly related with multifocality.
CONCLUSION
The results of this study showed that multifocal tumors were significantly associated with age, tumors size, capsular invasion, ETE and cervical LN metastasis in patients with PTC. LN metastasis was mostly influenced by multifocality in the PTC patients. It seems certain that total thyroidectomy and formal central node dissection with postoperative adjuvant therapy are essential treatment for these patients, and closely surveying the nodal status is needed on the follow up of patients with multifocal PTC.

Keyword

Papillary thyroid carcinoma; Multifocality; Lymph node metastasis

MeSH Terms

Classification
Diagnosis
Female
Follow-Up Studies
Humans
Lymph Nodes
Male
Neoplasm Metastasis
Prognosis
Recurrence
Retrospective Studies
Risk Factors
Thyroid Gland*
Thyroid Neoplasms*
Thyroidectomy

Reference

1.Sosa J., Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006. 94:701–7.

2.Grebe SK., Hay ID. Follicular cell-derived thyroid Carcinomas. Cancer Treat Res. 1997. 89:91–140.

3.Gulcelik MA., Gulcelik NE., Kuru B., Camlibel M., Alagol H. Prognostic factors determining survival in differentiated thyroid cancer. J Surg Oncol. 2007. 96:598–604.

4.Katoh R., Sasaki J., Kurihara H., Suzuki K., Iida Y., Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer. 1992. 70:1585–90.

5.Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998. 338:297–306.

6.Pellegriti G., Scollo C., Lumera G., Regalbuto C., Vigneri R., Belfiore A. Clinical behavior and outcome of papillany thyroid cancers smaller than 1.5 cm in diameter: Study of 299 cancer. J Clin Endocrinol Metab. 2004. 89:3713–20.

7.Lin JD., Chao TC., Hsueh C., Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol. 2009. 16:2609–16.

8.Mazzaferri EL., Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994. 97:418–28.

9.Loh KC., Greenspan FS., Gee L., Miller TR., Yeo PP. Pathological tumor node metastasis (pTNM) staging of papillary and follicular thyroid carcinomas: Retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997. 82:3553–62.

10.Chow M., Law SC., Chan JK., Au SK., Yau S., Lan WH. Papillry microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003. 98:31–40.

11.Park SY., Park YJ., Lee HS., Choi SH., Choe G., Jang HC, et al. Analysis of differential BRAF V600E mutational status in multifocal papillary thyroid carcinoma. Cancer. 2006. 107:1831–8.

12.Giannini R., Ugolini C., Lupi C., Proietti A., Elisei R., Salvatore G, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007. 92:3511–6.

13.Shattuck TM., Westra WH., Ladenson PW., Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005. 352:2406–12.

14.Sugg SL., Ezzat S., Rosen IB., Freeman JL., Asa SL. Distinct multiple RET/PTC gene rearrangement in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998. 83:4116–22.

15.McCarthy RP., Wang M., Jones TD., Strate RW., Cheng L. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res. 2006. 12:2412–8.

16.Hay ID., Gran CS., van Heerden JA., Goellner JR., Ebersold JR., Bergstralh EJ. Papillary thyroid microcarcinoma: A study of 535 canes observed in a 50-year period. Surgery. 1992. 112:1139–46.

17.Pasieka JL., Thompson NW., McLeod MK., Burney RE., Macha M. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg. 1992. 16:711–6.

18.DeGroot LJ., Kaplan EL. Second operations for ‘completion' of thyroidectomy in treatment of differentiated thyroid cancer. Surgery. 1991. 10:936–40.

19.Pacini F., Elisei R., Capezzone M., Miccoli P., Molinaro E., Basolo F, et al. Contralateral papillary thyroid cancer is freguent at completion thyroidectomy with no difference in low- and high-risk patiens. Thyroid. 2001. 11:877–81.

20.Hundahl SA., Fleming ID., Fremgen AM., Menck HR. A national cancer data base report on 53.856 cases thyroid carcinoma treated in the LIS,1985-1995. Cancer. 1998. 83:2638–48.

21.Kasai N., Sakamoto A. New subgrouping of small thyroid carcinomas. Cancer. 1987. 60:1767–70.

22.Park HL., Kwak JK., Kang SS., Kim DY., Kang HG., Shin JY, et al. The analysis of tumor aggressiveness according to tumor size in occult papillary thyroid carcinoma. J Korean Surg Soc. 2007. 73:470–5.

23.Appetecchia M., Scarcello G., Pucci E., Procaccini A. Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res. 2002. 21:159–64.

24.Cooper DS., Doherty GM., Haugen BR., Kloos RT., Lee SL., Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006. 16:109–42.

25.Bierley JD., Panzeralla T., Tsang RW., Gospodarowicz MK., O'Sullivan B. A comparison of different staging system predictability of patient outcome: Thyroid carcinoma as an examle. Cancer. 1997. 79:2414–23.

26.Passler C., Prager G., Schenba C. Application of staging system for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann Surg. 2003. 237:227–34.